BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, July 23, 2026
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
July 11, 2007
View Archived Issues
Silence Signs AstraZeneca To $400M Respiratory Drug Deal
In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)
Read More
CureVac Receives €13M To Boost mRNA Cancer Vaccines
No Abstract
Read More
One Bad SNP Carries Variant Linked To Bowel Cancer Risk
Read More
Neuropharm Gets Patients' Group Support For Autism Program
Read More
Other News To Note
Read More
GW Expands Cannabis Franchise Into CNS, Oncology Indications
Read More
EU Prediction: Europe's Biotech Future Will Depend On Change
Read More
To-BBB Raises $5.4 Million For CNS Drug Delivery
Read More
